Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $11.90, for a total transaction of $23,800.00. Following the transaction, the president now directly owns 2,877,138 shares of the company’s stock, valued at $34,237,942.20. This represents a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total transaction of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.43, for a total transaction of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total transaction of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total transaction of $9,560.56.

Gyre Therapeutics Price Performance

NASDAQ GYRE opened at $11.62 on Thursday. The company’s 50-day simple moving average is $11.17 and its 200 day simple moving average is $12.35. Gyre Therapeutics, Inc. has a twelve month low of $8.26 and a twelve month high of $26.37.

Institutional Trading of Gyre Therapeutics

Several large investors have recently added to or reduced their stakes in GYRE. Charles Schwab Investment Management Inc. grew its stake in Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after buying an additional 90,557 shares during the last quarter. Advantage Alpha Capital Partners LP bought a new stake in Gyre Therapeutics during the third quarter worth about $334,000. FMR LLC bought a new stake in Gyre Therapeutics during the third quarter worth about $47,000. State Street Corp grew its stake in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after buying an additional 8,412 shares during the last quarter. Finally, Barclays PLC grew its stake in Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after buying an additional 6,855 shares during the last quarter. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.